I have always thought the NEU strategy was (can’t remember what lead me to this) that Trofenitide would be sold as a stand alone drug, and that enough work would be done on NNZ-2591 to realize optimum value, with an ultimate sale of the drug in total.
Ill admit that things seem to have moved from there - to NEU possibly going the whole way alone / but the bottom line is that if a sale was to materialise for NEU I never thought that Trofenitide would be part of it.
So the RoW rights doesn’t impact this approach.
Acadia, page-56
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.21 |
Change
-0.130(0.85%) |
Mkt cap ! $1.944B | |||
| Open | High | Low | Value | Volume |
| $15.19 | $15.47 | $15.07 | $6.450M | 422.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1938 | $15.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.29 | 54 | 1 |
View Market Depth
| Last trade - 16.10pm 29/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |